HIV outcomes in hepatitis B virus coinfected individuals on HAART

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 2, 2014, Pages 197-205

  Chun, Helen M ^a   Mesner, Octavio ^a   Thio, Chloe L ^b   Bebu, Ionut ^a   Macalino, Grace ^a   Agan, Brian K ^a   Bradley, William P ^a   Malia, Jennifer ^a,c   Peel, Sheila A ^a,c   Jagodzinski, Linda L ^a,c   Weintrob, Amy C ^a,d   Ganesan, Anuradha ^a,d   Bavaro, Mary ^a,e   Maguire, Jason D ^a,f   Landrum, Michael L ^g  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^g Bellin Health   (United States)

Author keywords

chronic hepatitis B; hepatitis B virus; highly active antiretroviral therapy; HIV

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS TENOFOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE PLUS TENOFOVIR; EMTRICITABINE; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHRONIC HEPATITIS; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DEATH; FEMALE; HAZARD RATIO; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84901491483     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000142     Document Type: Article

References (36)

1. Gilson RJC, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597-606. (Pubitemid 27135881)
2. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:571-577. (Pubitemid 37011810)
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641. (Pubitemid 44232373)
4. Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HCV co-infections. J HIV Ther. 2003;8:77-84.
5. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-1926. (Pubitemid 35472132)
6. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49(5 suppl):S138-S145.
7. Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HIVinfected homosexual men are associated with more rapid progression to AIDS. AIDS. 1992;6:571-574.
8. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med. 1992;117:837-838.
9. Sinicco A, Raiteri R, Sciandra M, et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29:111-115.
10. Solomon RE, Van Raden M, Kaslow RA, et al. Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 HIV-1infection. Am J Public Health. 1990;80:1475-1478.
11. Greenspan D, Greenspan JS, Overby G, et al. Risk factors for rapid progression from hairy leukoplakia to AIDS: a nested case-control study. J Acquir Immune Defic Syndr. 1991;4:652-658.
12. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIVinfected patients. Prevalence and prognostic value. J Hepatol. 1997;27: 18-24. (Pubitemid 27357049)
13. Chun HM, Fieberg AM, Hullsiek KH, et al. The epidemiology of hepatitis B virus infection in a U.S. cohort of HIV-infected individuals during the last 20 years. Clin Infect Dis. 2010;50:426-436.
14. de Luca A, Bugarinin R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med. 2002;162:2125-2132. (Pubitemid 35168221)
15. Omland N, Skinhøj P, Laursen A, et al. Impact of hepatitis B virus coinfection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med. 2008;9:300-306. (Pubitemid 351517277)
16. Konopnicki D, Mocroft A, De WS, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593-601. (Pubitemid 40543982)
17. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23:1881-1889.
18. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4:241-249. (Pubitemid 36949880)
19. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47:1479-1485.
20. lsa SE, Gwamzhi LN, Akolo C, et al. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus coinfection in Jos, Nigeria. Niger J Med. 2010;19:279-285.
21. Moore E, Beadsworth MB, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect. 2010;61:155-163.
22. Idoko J, Meloni S, Muazu, et al. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009; 49:1268-1273.
23. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis coinfection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169-1177. (Pubitemid 38738516)
24. Hawkins C, Christian B, Ye J, et al. Prevalence of hepatitis B coinfection and response to antiretroviral therapy among HIV-infected patients in urban Tanzania. AIDS. 2013;27:919-927.
25. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38: 1471-1477.
26. Sheng WH, Kao JH, Chen PJ, et al. Evaluation of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45:1221-1229.
27. Thio CL, Smeaton L, Saulynas M, et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS. 2013;27:191-201.
28. Wandeler G, Gsponer T, Bihl F, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis. 2013;208:1454-1458.
29. Brodine SK, Starkey MJ, Shaffer RA, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17:2521-2527. (Pubitemid 38393326)
30. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 2008 revision. 2008. Available at: http://aidsinfo.nih.gov/ContentFiles/AboutHIVTreatmentGuidelines FS en.pdf. Accessed September 8, 2008.
31. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:No-RR17. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed January 4, 2008.
32. Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, L2ogistic Regression, and Survival Analysis. New York: Springer; 2001.
33. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010. Available at: http://www.R-project.org. Accessed November 1, 2011.
34. Marconi VC, Grandits GA, Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther. 2010;7:14.
35. Lifson AR, Krantz EM, Eberly LE, et al. Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther. 2011;8:2.
36. SMART Study Group, El-Sadr WM, Grund B, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149:289-299.